EC approves kyprolis® for combination use in the treatment of relapsed multiple myeloma
First irreversible proteasome inhibitor for relapsed multiple myeloma approved in the European Union
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Legislation & regulation Oncology ASPIRE trial ENDEAVOR trial kyprolis Latest News protease inhibitor relapsed multiple myeloma Source Type: news